First CRISPR Sickle Cell Patient ‘Reborn’: FDA Approves Treatment

The FDA's approval of Casgevy, which uses the Nobel Prize-winning gene-editing therapy to treat patients with sicke cell disease, opens the door to many other therapies.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Tags: Healthcare /healthcare Innovation /innovation Editors' Pick editors-pick business pharma & standard Source Type: news